本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Viking Therapeutics, Inc.

26.03
-0.8000-2.98%
成交量:131.27萬
成交額:3,456.23萬
市值:29.27億
市盈率:-16.94
高:27.04
開:26.55
低:25.96
收:26.83
52周最高:81.73
52周最低:18.92
股本:1.12億
流通股本:1.10億
量比:1.20
換手率:1.19%
股息:- -
股息率:- -
每股收益(TTM):-1.5368
每股收益(LYR):-1.0085
淨資產收益率:-19.99%
總資產收益率:-14.99%
市淨率:3.68
市盈率(LYR):-25.81

資料載入中...

2024/10/28

關聯方擬減持公告

Form 144 | Viking Therapeutics高管Greg Zante擬減持131687股,總價約1028萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 擬減持11000股,總價約88.94萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Singleton擬減持16000股,總價約127萬美元
2024/10/23

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Greg Zante擬減持16136股,總價約92.2萬美元
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Brian Lian擬減持115,859股,總價約667萬美元
2024/07/30

關聯方擬減持公告

Form144 | Viking Therapeutics高管Marianna Mancini擬減持18026股,總價約102.99萬美元
2024/07/25

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/25

重要事件披露

Form 8-K - Current report
2024/06/04

重要事件披露

Form 8-K - Current report
2024/05/23

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments